An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Trial Status: closed to accrual
This is a study to assess the safety of increasing dose levels of bexmarilimab when
combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or
chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to
identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety,
tolerability and pharmacological activity; Phase 2 will investigate the preliminary
efficacy of the combination treatment in selected indications from Phase 1.
Inclusion Criteria
Patient ≥ 18 years of age who presents with one of the following conditions:
Morphologically confirmed diagnosis of MDS with revised International Prognostic Scoring System (rIPSS) risk categories: intermediate, high and very high.
Morphologically confirmed diagnosis of CMML-2 with indication for azacitidine treatment.
CMML and MDS patient with response failure to HMA or therapy regimen including HMA.
Morphologically confirmed diagnosis of r/r AML following at least 1 line of prior therapies with indication for azacitidine treatment.
Morphologically confirmed diagnosis of AML in patients unfit for induction therapy with indication for azacitidine-venetoclax treatment.
Leukocyte count < 20 x10^9/L (< 25 x10^9/L for newly diagnosed AML). Hydroxycarbamide use is permitted to meet this criterion in MDS and AML but not in CMML.
Adequate renal function.
Adequate liver function.
Exclusion Criteria
Patient with acute promyelocytic leukemia (APL) or myeloproliferative CMML as defined by leukocyte count > 13 x10^9/L.
Eastern Cooperative Oncology Group (ECOG) performance status >2 (except newly diagnosed AML where ECOG 3 is allowed for patients < 75 years).
Allogeneic transplantation less than 6 months prior screening.
Patient with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).
The patient requires systemic corticosteroid (≥10 mg/day prednisone or equivalent) or other immunosuppressive treatment.
Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than 14 days or five half-lives (whichever is shorter) from a small molecule targeted therapy or oral anticancer chemotherapy before the first study treatment.
Any immunotherapy or investigational therapy within preceding 28 days from the first study treatment.
Pregnant or lactating women.
History of chronic ulcers or clinically relevant liver disease leading to Child Pugh Score C or higher.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05428969.
Locations matching your search criteria
United States
Connecticut
New Haven
Yale University
Status: Temporarily closed to accrual
Name Not Available
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: Active
Name Not Available
This is a multicenter Phase 1/2 open-label, study to assess the safety, tolerability and
preliminary efficacy of increasing doses of bexmarilimab (FP-1305) in patients with
intermediate, high or very high-risk MDS, CMML with 10-19 % marrow blasts, CMML/MDS with
failure to hypomethylating agent (HMA), or in patients with newly diagnosed AML non-fit
for induction therapy or relapsed/refractory AML. The Phase 1 part of the study will
identify a safe and tolerable bexmarilimab dose amongst four predefined dose levels using
a bayesian optimal interval (BOIN) dose escalation design to identify the maximum
tolerated dose (MTD) of bexmarilimab when administered in combination with SoC.
The Phase 2 of the study is an expansion phase to further evaluate the safety and
preliminary efficacy of bexmarilimab treatment at RP2D combined with SoC and will follow
a Simon's 2-stage design for each of the indications selected to continue forward from
Phase 1. This design allows for the investigation of bexmarilimab activity and
preliminary response assessments tailored to each indication and allows early stopping in
case of futility using a minimum number of patients. Patients from Phase 1, with the
selected indication to be investigated in Phase 2, that have been treated at RP2D may be
counted towards the number of patients for Phase 2.
Both study phases consist of a screening period, a treatment period, an end of treatment
(EoT) as safety follow-up and disease progression/survival follow-up.
